Doebar Shusma C, Slaets Leen, Cardoso Fatima, Giordano Sharon H, Bartlett John Ms, Tryfonidis Konstantinos, Dijkstra Nizet H, Schröder Caroline P, van Asperen Christi J, Linderholm Barbro, Benstead Kim, Dinjens Winan Nm, van Marion Ronald, van Diest Paul J, Martens John Wm, van Deurzen Carolien Hm
Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
The European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Mod Pathol. 2017 Apr;30(4):509-518. doi: 10.1038/modpathol.2016.229. Epub 2017 Jan 13.
In men, data regarding breast cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive male breast cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 male breast cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of breast cancer precursor lesions. In a subset, invasive breast cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive breast cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (<1%). In the subset of invasive breast cancer cases with adjacent ductal carcinoma in situ (n=83), a complete concordance was observed between the estrogen receptor, progesterone receptor, and HER2 status of both components. Next generation sequencing on a subset of cases with invasive breast cancer and adjacent ductal carcinoma in situ (n=4) showed identical genomic aberrations, including PIK3CA, GATA3, TP53, and MAP2K4 mutations. Next generation sequencing on a subset of cases with invasive breast cancer and an adjacent columnar cell-like lesion showed genomic concordance in two out of three patients. A multivariate Cox model for survival showed a trend that the presence of ductal carcinoma in situ was associated with a better overall survival, in particular in the Luminal B HER2+ subgroup. In conclusion, ductal carcinoma in situ is the most commonly observed precursor lesion in male breast cancer and its presence seems to be associated with a better outcome, in particular in Luminal B HER2+ cases. The rate of lobular carcinoma in situ and columnar cell-like lesions adjacent to male breast cancer is very low, but our findings support the role of columnar cell-like lesions as a precursor of male breast cancer.
在男性中,关于乳腺癌致癌作用的数据有限。我们研究的目的是描述浸润性男性乳腺癌旁前体病变的存在情况,以增进我们对这些患者致癌作用的理解。对1328例男性乳腺癌患者进行了中心病理学回顾,这些患者登记于国际男性乳腺癌项目的回顾性联合分析中,该分析包括乳腺癌前体病变的存在情况和类型。在一个亚组中,通过免疫组织化学(n = 83)或靶向二代测序(n = 7)将浸润性乳腺癌与其相邻的前体病变进行比较。此外,我们将导管原位癌的存在情况与预后相关联。相当一部分(46.2%)浸润性乳腺癌患者也有相邻的前体病变,主要是导管原位癌(97.9%)。小叶原位癌和柱状细胞样病变的存在率非常低(<1%)。在有相邻导管原位癌的浸润性乳腺癌病例亚组(n = 83)中,两个成分的雌激素受体、孕激素受体和HER2状态完全一致。对有浸润性乳腺癌和相邻导管原位癌的病例亚组(n = 4)进行的二代测序显示出相同的基因组畸变,包括PIK3CA、GATA3、TP53和MAP2K4突变。对有浸润性乳腺癌和相邻柱状细胞样病变的病例亚组进行的二代测序显示,三分之二的患者基因组一致。生存的多变量Cox模型显示出一种趋势,即导管原位癌的存在与更好地总生存相关,特别是在Luminal B HER2+亚组中。总之,导管原位癌是男性乳腺癌中最常见的前体病变,其存在似乎与更好的预后相关,特别是在Luminal B HER2+病例中。男性乳腺癌旁小叶原位癌和柱状细胞样病变的发生率非常低,但我们的研究结果支持柱状细胞样病变作为男性乳腺癌前体的作用。